Pharmacokinetic and Pharmacodynamic Study of a Novel Sublingual Aspirin Tablet
Pharmacokinetic and Pharmacodynamic Study of a Novel Sublingual Aspirin Tablet Compared to Conventional Oral Aspirin in Healthy Subjects
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Rolley Lee
- Phone Number: +852 29035983
- Email: rolley.lee@vitagreen.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male, 18 to 55 years of age
- Body mass index between 18-27kg/m2
- Accessible vein for blood sampling
- High probability for compliance and completion of the study
- No significant abnormalities in general physical examination
- Subjects must agree to take effective contraceptive methods to prevent his partner pregnant during the time of first dose of study medication until one week of last dose administration
Exclusion Criteria:
- History of hepatic, renal, biliary, cardiovascular, gastrointestinal, haematological and other chronic and acute diseases within 3 months prior to screening
- Clinically relevant abnormality in physical examination, ECG evaluation, urine test, blood chemistry or haematological test at the discretion of the investigator
- Positive results for hepatitis B at screening
- Moderate smoker (on average more than 2 cigarettes a day within 1 month prior to the start of first dosing)
- Moderate consumption of alcohol (on average more than one drink per day within 1 month prior to start of first dosing)
- Blood donation of more than 350 ml within 4 weeks prior to start of first drug dosing
- Treatment of aspirin within 4 weeks before first dosing
- Volunteer in any other clinical drug study within 2 months prior to start of first dosing
- Hypersensitivity to aspirin or other drug in its class
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Healthy volunteer
Sublingual or oral aspirin 80mg tablet, single dose, two-treatment, two-period, two-sequence, randomized, crossover design, with washout 1-2 weeks
|
Vita Green Health Products sublingual aspirin 80 mg tablet
Synco (HK) oral aspirin 80mg tablet
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Plasma-concentration time data of salicylic acid
Time Frame: pre dose and up to 24 hour post dose
|
area under the plasma concentration-time curve from time zero to last measurable concentration time point for sublingual versus oral aspirin 80mg
|
pre dose and up to 24 hour post dose
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Peak plasma concentration of salicylic acid
Time Frame: pre dose and up to 24 hour post dose
|
Peak plasma concentration for sublingual versus oral aspirin 80mg
|
pre dose and up to 24 hour post dose
|
|
Time to reach peak plasma concentration of salicylic acid
Time Frame: pre dose and up to 24 hour post dose
|
Tmax of sublingual versus oral aspirin 80mg
|
pre dose and up to 24 hour post dose
|
|
Terminal phase elimination rate constant of salicylic acid
Time Frame: pre dose and up to 24 hour post dose
|
Terminal phase elimination rate constant of sublingual versus oral aspirin 80mg
|
pre dose and up to 24 hour post dose
|
|
Terminal elimination half-life of salicylic acid
Time Frame: pre dose and up to 24 hour post dose
|
Terminal elimination half-life of sublingual versus oral aspirin 80mg
|
pre dose and up to 24 hour post dose
|
|
Plasma concentration time data of thromboxane B2
Time Frame: pre dose and up to 24 hour post dose
|
Area under the curve for sublingual versus oral aspirin 80mg
|
pre dose and up to 24 hour post dose
|
|
Platelet aggregation by impedance aggregometry
Time Frame: pre dose and up to 360 minutes post dose
|
Differences in platelet aggregation with sublingual versus oral aspirin 80mg
|
pre dose and up to 360 minutes post dose
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Platelet Aggregation Inhibitors
- Cyclooxygenase Inhibitors
- Antipyretics
- Aspirin
Other Study ID Numbers
Other Study ID Numbers
- VG-BABE-19-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.